Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thiotepa and busulfan combined with cyclophosphamide conditioning regimen plus maintenance therapy improved the disease-free survival of patients with relapsed/refractory haematologic malignancies after undergoing allogeneic transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRui CuiQMQiaoling MaJWJialin Wei

Discussion

Loading...

Member takes

Overview

Retrospective analysis found that thiotepa and busulfan regimen improves disease-free survival in patients after haematopoietic stem cell transplantation, suggesting safer options for treatment.

Key Points

  • Disease-free survival improved with a thiotepa and busulfan regimen in patients with haematologic malignancies undergoing transplant.
  • 85.2% of patients achieved overall survival at 1 year following allogeneic transplantation.
  • Retrospective analysis of conditioning regimen efficacy in the context of haematopoietic stem cell transplantation.
  • Findings suggest potential for thiotepa-based therapies in managing relapsed/refractory malignancies post-transplant.

Cite This Study

Cui et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db95https://doi.org/10.1182/blood-2025-5974
View Full Paper
Ask AI
Bookmark
Share